期刊文献+

血管免疫母细胞性T细胞淋巴瘤42例临床分析 被引量:10

Angioimmunoblastic T cell lymphoma: clinical analysis of 42 cases
原文传递
导出
摘要 目的 分析血管免疫母细胞性T细胞淋巴瘤(AITL)的临床特征及预后因素.方法 回顾性分析2007年1月至2012年8月在北京大学肿瘤医院住院治疗的初治42例AITL患者的临床资料,总结其临床特征并分析其预后因素.结果 42例患者的中位年龄为59岁(年龄范围34 ~ 76岁),其中97.6% (41/42)为Ⅲ~Ⅳ期患者,73.8% (31/42)伴有B症状;85.7%(36/42)以无痛性浅表淋巴结肿大起病;52.4%(22/42)出现结外受侵;64.3%(27/42)起病时乳酸脱氢酶升高;45.2%(19/42)β2-微球蛋白升高;淋巴瘤国际预后指数(IPI)评分达3分即中高危组所占比例最高,占40.5% (17/42).一线治疗主要采用CHOP(环磷酰胺、阿霉素、长春新碱、泼尼松)类方案化疗,44.7%(17/38)获完全缓解.中位随访时间40个月(2~106个月).1、2和5年生存率分别为78%、57%和39%.统计学分析显示IPI评分为患者独立预后因素(P =0.009),其余因素包括性别(P=0.311)、年龄(P=0.263)、是否伴有B症状(P =0.102)、Ki-67指数(P =0.146)以及一线化疗方案的选择(P=0.292)均有影响生存的趋势,但尚未具有统计学意义.结论 AITL发病年龄偏大,分期晚,预后不佳.IPI评分为患者独立预后因素,患者的性别、年龄、是否伴有B症状、Ki-67指数以及一线化疗方案的选择可能有影响生存的趋势. Objective To explore the clinical characteristics and prognosis of patients with angioimmunoblastic T cell lymphoma (AITL).Methods The clinical features and prognostic factors of 42 cases newly diagnosed as AITL at Peking University Cancer Hospital from January 2007 to August 2012 were retrospectively analyzed.Results Their median age was 59 (34-76) years.Among them,97.6% cases (41/42) belonged to Ann Arbor stage Ⅲ/Ⅳ,73.8% (31/42) cases presented with B symptoms,85.7% (36/42) cases had painless lymphadenopathy,52.4% (22/42) cases extranodal involvement,64.3% (27/42) cases elevated lactate dehydrogenase and 45.2% (19/42) cases elevated ββ2-microglobulin at diagnosis.And 40.5% (17/42) cases had 3 points of international prognostic index (IPI) score with the highest proportion.First-line chemotherapy was predominantly CHOP (cyclophosphamide,vincristine,doxorubicin,prednisolone) or CHOP-like-based and complete response was achieved in 44.7% (17/38) of them.The median follow-up time was 40(2-106) months The 1,2,5-year survival rates were 78%,57% and 39% respectively.Statistical analysis showed that IPI was an independent prognostic factor (P =0.009).Other factors included gender (P =0.311),age (P =0.263),with or without B symptoms (P =0.102),Ki-67 index (P =0.146) as well as the choice of first-line chemotherapy (P =0.292) each had a tendency of affecting; the survival rate,but failed to reach statistical significance.Conclusions Angioimmunoblastic T-cell lymphoma is a major type of peripheral T-cell lymphoma.Most AITL patients are elders with a late stage.The disease generally displays an aggressive clinical course and poor prognosis.
出处 《中华医学杂志》 CAS CSCD 北大核心 2013年第46期3671-3674,共4页 National Medical Journal of China
关键词 淋巴瘤 预后 血管免疫母细胞性T细胞淋巴瘤 临床特征 Lymphoma Prognosis Angioimmunoblastic T cell lymphoma Clinicalcharacteristics
  • 相关文献

参考文献16

  • 1Good D J, Gascoyne RD. Classification of non-Hodgkin' s lymphoma. Hematol Oncol Clin North Am,2008,22:781-805.
  • 2Smith JL, Hodges E, Quin CT, et al. Frequent T and B cell oligoclones in histologically and immunophenotypically characterized angioimmunoblastie lymphadenopathy. Am J Pathol, 2000,156:661-669.
  • 3Dogan A, Attygalle AD, Kyriakou C. Angioimmunoblastic T-cell lymphoma. Br J Haematol,2003 ,121:681-691.
  • 4Horwitz SM. Novel therapies and role of transplant in the treatment of peripheral T-cell lymphomas. Hematology Am Soc Hematol Educ Program,2008 : 289-296.
  • 5Pautier P, Devidas A, Delmer A, et al. Angioimmunoblastie-like T- cell non Hodgkin's lymphoma: outcome after chemotherapy in 33 patients and review of the literature. Leuk Lymphoma, 1999,32: 545 -552.
  • 6Cheson BD ,Pfistner B ,Juweid ME ,et al. Revised response criteria for malignant lymphoma. J Clin Onco1,2007,25:579-586.
  • 7Mourad N, Mounier N, Bri~re J, et al. Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte ( GELA ) trials. Blood,2008,111:4463-4470.management of angioimraunohlastic T-call.
  • 8de Leval L, Gisselbrecht C, Gaulard P. Advances in the understanding and lymphomz. Br J Haematol,2010,148:673-689.
  • 9Lin HN, Liu CY, Hong YC, et al. Clinical features and prognostic factors of angioimmunoblastic T-cell lymphoma in Taiwan: a single-institution experience. Leuk Lymphoma, 2010, 51 : 2208- 2214.
  • 10Siegert W, Ned C, Agthe A, et al. Angioimmunoblastic lymphadenopathy (AILD)-type T-cell lyrnphoma: prognostic impact of clinical observations and laboratory findings at presentation. The Kiel Lymphoma Study Group. Ann Oncol, 1995, 6:659-664.

同被引文献65

  • 1肖畅,苏祖兰,吴秋良,郜红艺,方建晨,夏忠军,管忠震.根据WHO新分类对493例非霍奇金淋巴瘤的临床病理分析[J].中华病理学杂志,2005,34(1):22-27. 被引量:54
  • 2Vose J, Armitage J, Weisenburger D. International T-Cell Lym- phoma Project.International Peripheral T-cell and Natural Killer/ T-Cell Lymphoma Study: Pathology Findings and Clinical Out- comes[J]. Clin Oncol, 2008, 26(25):4124-4130.
  • 3Jaffe ES, Ralfldaer E. Angioimmunobalstic T-cell lymphoma[M]//Jaffe ES, Harris NL, Stein H, et al. World Health Organisation Classfifi- cation of Tumours. Patholoyg and genetics of tumours of haemato- poietic and lymphoid tissues[J]. Lyon: IARC Press, 2001: 225-226.
  • 4Cheson BD, Pfsmer B, Juweid ME, et al. Revised response criteria for malignant lymphoma[J].J Clin 0ncol, 2007, 25(5):579-586.
  • 5Mourad N, Mounier N, BriereJ, et al, Clinical,biologic,and patho- logic features in 157 patients within angioimmunoblasfic T-ceUlymphoma treated within the Group Etude des Lymphomes de Adulte(CELA)trials[J]. Blood, 2008, 111(9):4463-4470.
  • 6Yuan CM, VergilioJA, Zhao XF, et al. CD10 and BCL6 expression in the diagnosis of angioimmunoblasfic T-cell lymphoma:utility of detecting CDI0+ T -cells by flow cytometry[J]. Hum Pathol, 2005, 36 (7):784-791.
  • 7Yu H, Shahsafaei A, Dorfman DM. Germinal-center T-helper-ceU markers PD- 1 and CXCL 13 are both expressed by neoplastic cells in angioimmunoblasfic T-ceU lymphoma[J]. AmJ Clin Pathol, 2009, 131(1):33-41.
  • 8Kim SJ, Yoon DH, Kang HJ, et al. Bortezomib in combination with CHOP as ftrst-line treatment for padents with stage Ⅲ/Ⅳ peripheral T-cell lymphomas:a muldcenter,single-arm,phase 2 trial[J]. Eur J Cancer, 2012, 48(17):3223-3231.
  • 9Pautier P, Devidas A, Delmer A, et al. Angioimmunoblastic-like T-cell non Hodgkin lymphoma:outcome after chemotherapiy in 33 patients and review of the fiterature[J]. Leuk Lymphoma, 1999, 32(5-6): 545-552.
  • 10Fabbfi A, Cercini E, Pieuini A, et al. Impressive activity of lenalidomide monotherapy in refactory angioimmunoblastic T-ceU lymphoma: report of a case with long-term follow-up[J]. Hermatol Oncol, 2013, 31(4):213-217.

引证文献10

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部